Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Salivary Gland Neoplasms 1Prostatic Neoplasms 1

Interventions

Specimen Handling 655pembrolizumab 605Magnetic Resonance Spectroscopy 562Carboplatin 445Cisplatin 396Cyclophosphamide 394Biopsy 378Nivolumab 323Paclitaxel 320Gemcitabine 313Radiotherapy 293Bevacizumab 248Dexamethasone 221fludarabine 212Docetaxel 201durvalumab 193atezolizumab 186Oxaliplatin 186venetoclax 182Fluorouracil 175Rituximab 173Pemetrexed 172Capecitabine 170Radiation 166Doxorubicin 166Radiosurgery 158Ipilimumab 145Etoposide 142Leucovorin 140Lenalidomide 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Androgen Receptor Antagonists × 90 days × Clear all
NCT04946370 2026-04-21

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Weill Medical College of Cornell University

Phase 1/2 Recruiting
52 enrolled
Genitourinary

Prostatic Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡